A5049310767- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Polyomavirus and related diseases
- Hepatitis B Virus Studies
- Renal Transplantation Outcomes and Treatments
- Potassium and Related Disorders
- Viral-associated cancers and disorders
- Medical Device Sterilization and Disinfection
- Nanowire Synthesis and Applications
- Cutaneous lymphoproliferative disorders research
- Assisted Reproductive Technology and Twin Pregnancy
- Hematological disorders and diagnostics
- Ovarian cancer diagnosis and treatment
- Monoclonal and Polyclonal Antibodies Research
- Reproductive Biology and Fertility
- COVID-19 and healthcare impacts
- Global Cancer Incidence and Screening
- Neuroendocrine Tumor Research Advances
- Integrated Circuits and Semiconductor Failure Analysis
- Virology and Viral Diseases
- IgG4-Related and Inflammatory Diseases
Okayama University Hospital
2017-2025
Okayama University
2022
Abstract Therapies that effectively suppress graft-versus-host disease (GVHD) without compromising graft-versus-leukemia/lymphoma (GVL) effects is important in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for malignancies. Geranylgeranylacetone (GGA) a main component of teprenone, gastric mucosal protectant commonly used clinical practice. In preclinical models, GGA suppresses proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α...
The advent of anti-CD19 chimeric antigen receptor-T cell therapy has dramatically changed the treatment strategy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Three products are recently available in Japan, but to best our knowledge, real-world data only tisagenlecleucel. This study was a retrospective analysis 27 patients who received axicabtagene ciloleucel (axi-cel) R/R DLBCL at institution. Cytokine release syndrome and immune effector cell-associated neurotoxicity...
Abstract Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease 2019 (COVID-19) a poor prognosis, as noted in several case reports who had COVID-19 before infusion. We report 70-year-old woman developed immediately CAR-T therapy for high-grade lymphoma. She received Tixagevimab−Cilgavimab chemotherapy...
Abstract This study investigated the efficacy of tisagenlecleucel (tisa-cel) and allogeneic hematopoietic stem cell transplantation (allo-SCT) for patients with relapsed and/or refractory (r/r) large B-cell lymphoma (LBCL) poor prognostic factors, defined as performance status (PS) ≥ 2, multiple extranodal lesions (EN), chemorefractory disease, or higher lactate dehydrogenase (LDH). Overall, allo-SCT group demonstrated worse progression-free survival (PFS), non-relapse mortality, a similar...
The prognostic impact of corticosteroid therapy in patients receiving tisagenlecleucel (tisa-cel) treatment who are more likely to develop cytokine release syndrome (CRS) remains unclear. This study aimed evaluate the clinical and lymphocyte kinetics administration for CRS 45 with relapsed and/or refractory B-cell lymphoma treated tisa-cel. was a retrospective evaluation all consecutive diagnosed diffuse large lymphoma, follicular histologic transformation or received commercial-based...
Objective Chimeric antigen receptor (CAR) T cell therapy is an emerging and effective for relapsed or refractory diffuse large B lymphoma (R/R DLBCL). The characteristic toxicities of CAR include cytokine release syndrome (CRS) prolonged cytopenia. We investigated the factors associated with these complications after by analyzing lymphocyte subsets following infusion. Methods retrospectively analyzed peripheral blood samples on days 7, 14, 28 tisagenlecleucel (tisa-cel) infusion flow...
Polyethylene glycol (PEG) is widely used for bowel cleaning in preparation colonoscopy because of its safety. Septic shock after PEG an extremely rare complication. Herein, we describe a case septic that occurred immediately with PEG. A 75-year-old Japanese male who had previously developed diabetes total pancreatectomy received colonoscopy. He been admitted to the emergency intensive care unit 4 days earlier due hematochezia presenting shock. ingested prepare examination, which was...
Distinguishing between IgG4-related disease (IgG4-RD) and hyper-interleukin (IL) -6 syndrome, such as immune mediated conditions, autoimmune diseases, idiopathic multicentric Castleman (iMCD) is challenging. Here, we report the case of a 69-year-old man with cervical lymphadenopathy who was admitted to our hospital histologically diagnosed hyper-IL-6 syndrome mimicking IgG4-RD phenotypically. Laboratory data detected polyclonal hypergammaglobulinemia comprising IgG, including IgG4 (2,350...
同種造血幹細胞移植後の婦人科系疾患に関する報告は少ない。当科は移植後女性患者の婦人科定期検診(内診,経膣超音波検査,子宮頸部細胞診)を実施している。本研究では当施設の移植後患者37例(年齢中央値50歳,18-73歳)を後方視的に解析した。細胞診異常を認めたのは8例で,全例にbusulfan投与歴があった。高度扁平上皮内病変は4例で,そのうち1例は膣がんを発症し,放射線治療を受けた。軽度上皮内病変は3例,非定型扁平上皮細胞は1例であった。膣がん症例以外の7例の細胞診異常は1年半以内に自然消退した。子宮頸がん,子宮内膜がん,卵巣がんの症例はなかった。移植後の婦人科系がんに関連する因子を特定するためにはさらなる分析が必要であるが,移植後の婦人科系疾患の早期発見・治療のため,問診方法を工夫し,婦人科受診を推奨することが重要であると考えられた。
Tisagenlecleucel(tisa-cel)輸注後早期(3ヶ月以内)の病勢増悪/再燃を予測する輸注前因子を明らかにするために,当院の42例を後方視的に解析した。Tisa-cel輸注後の観察期間中央値:8.2ヶ月(範囲:0.2-36.5)で,16例(38.1%)が早期に病勢増悪/再燃した。リンパ球採取前の "primary refractory" 症例,リンパ球除去化学療法前のLDH高値(>1.5×upper limit of normal)および節外病変≥2は,tisa-cel輸注後早期の病勢増悪/再燃を予測する輸注前因子であった。特に,de novo DLBCLかつ な臨床経過を有する9/10例(90%)は輸注後4ヶ月以内に病勢増悪したため,この患者群において新たな治療戦略を検討する事の重要性が示唆された。
A 73-year-old male with melena was admitted to our hospital. Computed tomography (CT) scan revealed the thickening of jejunal and ileal walls swelling mesenteric lymph nodes. Type II enteropathy-associated T-cell lymphoma (EATL) diagnosed based on pathological analysis resected specimen. Positron emission CT showed complete remission (CR) after surgery, he further received CHOP therapy. However, 2 months completion therapy, patient's disease relapsed, presented abdominal pain. Ifosfamide,...
Vaccine-preventable disease (VPD) infections are more severe in immunocompromised hosts. Vaccination against measles, mumps, rubella, and varicella zoster (VZV) (MMRV) is therefore recommended for hematopoietic stem cell transplantation (HCT) recipients. However, studies on adult HCT recipients with VPD limited. At our institution, we have systematically conducted serological MMRV tests as a part of check-up examinations during long-term follow-up (LTFU) after since 2015. This retrospective...
造血幹細胞移植患者に対する就労支援と就学支援の2021年現在の実践状況を明らかにするため,中国地方の血液内科と小児血液腫瘍科の25施設31名の医師にアンケートを送付し,18施設,23名(74%)から回答を得た。就労支援の窓口は12施設(67%)が開設していたが,相談件数は半数以上が年間0件であった。自施設の就労支援体制について十分であると評価したのはわずか3名(14%)であった。就学支援の経験がある血液内科医は17名中3名(18%)と少なかった。7名(41%)がオンライン授業の経験があると回答した。自施設の高校生・大学生の就学支援体制について全ての施設が十分でないと回答した。これらの結果により,就労・就学支援体制は施設により差があり,改善の余地があることが明らかになった。多職種,他機関との協力関係を構築し,AYA世代を含む全ての患者を支援する体制の必要性が示唆された。
We interviewed the adult and pediatric hematologists in Chugoku Shikoku regions order to determine their opinions attitudes about fertility preservation 2020. A questionnaire on practices was sent 59 doctors 46 hematology-oncology hospitals, out of which 52 (88.1%) responded. Forty (76.9%) had no rules explanation 37 (71.2%) answered that attending physicians provided alone hospitals. Many target age group patients. Only few hospitals were able complete treatment hematological malignancies...